Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11069163 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL17520885 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL17521190 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL5310242 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL509770 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL24914761 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL19343098 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| Hydrochloric Acid SCHEMBL11869519 | 0.98 | L3MBTL3 (0.44) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL10948177 | 0.97 | L3MBTL3 (0.47) | L3MBTL3ALDH1A1L3MBTL1OPRM1OPRL1 | |
| SCHEMBL19343093 | 0.97 | L3MBTL3 (0.47) | L3MBTL3ALDH1A1L3MBTL1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | L3MBTL3 1746/4885CYP1A2 1915/4885ALDH1A1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.